New Delhi, India – 110 016
South Delhi Pharma, New Delhi, India
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.
Soliris is a prescription medicine. Soliris used for Paroxysmal Nocturnal Hemoglobinuria (PNH).
INDICATIONS AND USAGE
Soliris is a complement inhibitor indicated for:
• The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
• The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (1.2).
The effectiveness of Soliris in aHUS is based on the effects on thrombotic microangiopathy (TMA) and renal function.
DOSAGE FORMS & STRENGTHS
300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
Manufactured By: Alexion Pharmaceuticals, Inc.
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “Soliris ® (eculizumab) Concentrated solution” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. It has been developed, manufactured, and marketed by Alexion Pharmaceuticals, which had patent exclusivity until 2017.
